The Food and Drug Administration approved Relypsa Inc.'s (Nasdaq: RLYP) Veltassa to treat hyperkalemia but the requirement for a box warning that Veltassa could potentially interfere with other drugs sent the stock price plunging $4.39 to close at $11.76.
Box warnings required for Relypsa
October 22, 2015 at 19:46 PM EDT
